ESMO 2022 on ctDNA Dynamics, CEA, and Sites of Recurrence for the Ra…

ESMO 2022 Conference Coverage

J. Tie

Lecture Summary - ESMO 2022 on Characterizing the Clinico-Genomic La…

ESMO 2022 Conference Coverage

F. Keane

ESMO 2022 on Characterizing the Clinico-Genomic Landscape and Outcom…

ESMO 2022 Conference Coverage

F. Keane

Lecture Summary - ESMO 2022 on the NuTide:302 Study: NUC-3373, a Pro…

ESMO 2022 Conference Coverage

A. Coveler

ESMO 2022 on the NuTide:302 Study: NUC-3373, a ProTide Transformatio…

ESMO 2022 Conference Coverage

A. Coveler

ESMO 2022 on the Global Phase 3 Multiregional Clinical Trial FRESCO-…

ESMO 2022 Conference Coverage

A. Dasari

ESMO 2022 on the Phase 3 HIMALAYA Study: Impact of Viral Aetiology o…

ESMO 2022 Conference Coverage

S. L. Chan

ESMO 2022 on KRYSTAL-1: Updated Efficacy & Safety of Adagrasib With/…

ESMO 2022 Conference Coverage

S. Klempner

Lecture Summary - ESMO 2022 on the Global Phase 3 Multiregional Clin…

ESMO 2022 Conference Coverage

A. Dasari

Lecture Summary - ESMO 2022 on the Updated Analysis of DESTINY-Gastr…

ESMO 2022 Conference Coverage

G. Ku

ESMO 2022 Updated Analysis of DESTINY-Gastric02 Trial: T-DXd in West…

ESMO 2022 Conference Coverage

G. Ku

Lecture Summary - ESMO 2022 on the Phase III ERMES Study: FOLFIRI/Ce…

ESMO 2022 Conference Coverage

A. Orlandi

ESMO 2022 on the Phase III ERMES Study: FOLFIRI/Cetuximab vs. FOLFIR…

ESMO 2022 Conference Coverage

A. Orlandi

ESMO 2022: Early Decreases in KRAS Mutant Allele Frequency Predicts …

ESMO 2022 Conference Coverage

H. Lenz

Lecture Summary - ESMO 2022: Beyond 1L for mCRC - Best Practices and…

ESMO 2022 Conference Coverage

T. Price

Beyond 1L for mCRC - Best Practices and Practical Nuances

Timothy Price

ESMO 2022 on Advances in HER2-Targeted Therapy or Novel Targeted The…

ESMO 2022 Conference Coverage

K. Shitara

Lecture Summary - ESMO 2022: Real-World Monitoring of ctDNA Reliably…

ESMO 2022 Conference Coverage

S. Cohen

ESMO 2022: Real-World Monitoring of ctDNA Reliably Predicts Cancer R…

ESMO 2022 Conference Coverage

S. Cohen

ESMO 2022 Final Analysis of the Randomized, Phase 3 RATIONALE-301 St…

ESMO 2022 Conference Coverage

M. Kudo

ESMO 2022 on the Updated OS From the Phase 3 TOPAZ-1 Study: Durvalum…

ESMO 2022 Conference Coverage

D. Oh

Lecture Summary - ESMO 2022 on 4.5-Year Follow-Up From KEYNOTE-240: …

ESMO 2022 Conference Coverage

J. Edeline

ESMO 2022 on 4.5-Year Follow-Up From KEYNOTE-240: Pembrolizumab vs. …

ESMO 2022 Conference Coverage

J. Edeline

ESMO 2022 on the NICHE-2 Study: Neoadjuvant Immune Checkpoint Inhibi…

ESMO 2022 Conference Coverage

M. Chalabi

Lecture Summary - ESMO 2022 on the HIPECT4 Randomized Phase 3 Study:…

ESMO 2022 Conference Coverage

A. Arjona-Sanchez

ESMO 2022 on the HIPECT4 Randomized Phase 3 Study: Adjuvant Hyperthe…

ESMO 2022 Conference Coverage

A. Arjona-Sanchez

Lecture Summary - ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase…

ESMO 2022 Conference Coverage

J. Taieb

ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase II Trial: Aveluma…

ESMO 2022 Conference Coverage

J. Taieb